Research: Liver Research Unit

Our publications

1. McCullen MA, Fletcher LM, Dimeski G, Pink A, Powell LW, Crawford DH, Hickman PE. Patient-focused outcomes following detection in a hospital-based screening programme for C282Y haemochromatosis. Intern Med J 2008;38:651-6.

2. Theurl M, Theurl I, Hochegger K, Obrist P, Subramaniam N, van Rooijen N, Schuemann K, Weiss G. Kupffer cells modulate iron homeostasis in mice via regulation of hepcidin expression. J Mol Med 2008;86:825-35.

3. Walker NA, Crawford DH, Subramaniam VN, Wallace DF. Juvenile iron overload--advances, but no answers. J Pediatr 2008;153:588.

4. Wallace DF, Summerville L, Crampton EM, Subramaniam VN. Defective trafficking and localization of mutated transferrin receptor 2: implications for type 3 hereditary hemochromatosis. Am J Physiol Cell Physiol 2008;294:C383-90.

5. Bridle KR, Popa C, Morgan ML, Sobbe AL, Clouston AD, Fletcher LM, Crawford DH. Rapamycin inhibits hepatic fibrosis in rats by attenuating multiple profibrogenic pathways. Liver Transpl 2009;15:1315-24.

6. Crawford D, Ramm GA. Utility of platelets and AST vs serum ferritin and serum hyaluronic acid as markers of cirrhosis in hemochromatosis. Hepatology 2009;49:1781-1782.

7. Crawford DC, Moulder KL, Gereau RWt, Story GM, Mennerick S. Comparative effects of heterologous TRPV1 and TRPM8 expression in rat hippocampal neurons. PLoS One 2009;4:e8166.

8. Crawford DH, Murphy TL, Ramm LE, Fletcher LM, Clouston AD, Anderson GJ, Subramaniam VN, Powell LW, Ramm GA. Serum hyaluronic acid with serum ferritin accurately predicts cirrhosis and reduces the need for liver biopsy in C282Y hemochromatosis. Hepatology 2009;49:418-25.

9. Heritage ML, Murphy TL, Bridle KR, Anderson GJ, Crawford DH, Fletcher LM. Hepcidin regulation in wild-type and Hfe knockout mice in response to alcohol consumption: evidence for an alcohol-induced hypoxic response. Alcohol Clin Exp Res 2009;33:1391-400.

10. Hickman IJ, Sullivan CM, Flight S, Campbell C, Crawford DH, Masci PP, O'Moore-Sullivan TM, Prins JB, Macdonald GA. Altered clot kinetics in patients with non-alcoholic fatty liver disease. Ann Hepatol 2009;8:331-8.

11. Landers KA, McKinnon BD, Li H, Subramaniam VN, Mortimer RH, Richard K. Carrier-mediated thyroid hormone transport into placenta by placental transthyretin. J Clin Endocrinol Metab 2009;94:2610-6.

12. Ramm GA, Shepherd RW, Hoskins AC, Greco SA, Ney AD, Pereira TN, Bridle KR, Doecke JD, Meikle PJ, Turlin B, Lewindon PJ. Fibrogenesis in pediatric cholestatic liver disease: role of taurocholate and hepatocyte-derived monocyte chemotaxis protein-1 in hepatic stellate cell recruitment. Hepatology 2009;49:533-44.

13. Roberts SK, Weltman MD, Crawford DH, McCaughan GW, Sievert W, Cheng WS, Rawlinson W, Desmond PV, Marks PS, Yoshihara M, Rizkalla B, Depamphilis JK, Dore GJ. Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial. Hepatology 2009;50:1045-55.

14. Ruddell RG, Knight B, Tirnitz-Parker JE, Akhurst B, Summerville L, Subramaniam VN, Olynyk JK, Ramm GA. Lymphotoxin-beta receptor signaling regulates hepatic stellate cell function and wound healing in a murine model of chronic liver injury. Hepatology 2009;49:227-39.

15. Topping KP, Fletcher LM, Agada FO, Alhamarneh O, Stafford ND, Greenman J. Head and neck tumour immunology: basic concepts and new clinical implications. J Laryngol Otol 2009;123:9-18.

16. Wallace DF, Summerville L, Crampton EM, Frazer DM, Anderson GJ, Subramaniam VN. Combined deletion of Hfe and transferrin receptor 2 in mice leads to marked dysregulation of hepcidin and iron overload. Hepatology 2009;50:1992-2000.

17. Cheng WS, Roberts SK, McCaughan G, Sievert W, Weltman M, Crawford D, Rawlinson W, Marks PS, Thommes J, Rizkalla B, Yoshihara M, Dore GJ. Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing. J Hepatol 2010;53:616-23.

18. Crawford D, Fletcher L, Stuart K. Ferritin and liver allocation? Impact on mortality not only on the waiting list but also after orthotopic liver transplantation shouldbe considered. Hepatology 2010;52:393.

19. Hopkins PM, Kermeen F, Duhig E, Fletcher L, Gradwell J, Whitfield L, Godinez C, Musk M, Chambers D, Gotley D, McNeil K. Oil red O stain of alveolar macrophages is an effective screening test for gastroesophageal reflux disease in lung transplant recipients. J Heart Lung Transplant 2010;29:859-64.

20. Jeffery JM, Urquhart AJ, Subramaniam VN, Parton RG, Khanna KK. Centrobin regulates the assembly of functional mitotic spindles. Oncogene 2010;29:2649-58.

21. McDonald CJ, Jones MK, Wallace DF, Summerville L, Nawaratna S, Subramaniam VN. Increased iron stores correlate with worse disease outcomes in a mouse model of schistosomiasis infection. PLoS One 2010;5:e9594.

22. Norgate M, Southon A, Greenough M, Cater M, Farlow A, Batterham P, Bush AI, Subramaniam VN, Burke R, Camakaris J. Syntaxin 5 is required for copper homeostasis in Drosophila and mammals. PLoS One 2010;5:e14303.

23. Walker NM, Stuart KA, Ryan RJ, Desai S, Saab S, Nicol JA, Fletcher LM, Crawford DH. Serum ferritin concentration predicts mortality in patients awaiting liver transplantation. Hepatology 2010;51:1683-91.

24. Wallace DF, Harris JM, Subramaniam VN. Functional analysis and theoretical modeling of ferroportin reveals clustering of mutations according to phenotype. Am J Physiol Cell Physiol 2010;298:C75-84.

25. Zou YH, Liu X, Khlentzos AM, Asadian P, Li P, Thorling CA, Robertson TA, Fletcher LM, Crawford DH, Roberts MS. Liver fibrosis impairs hepatic pharmacokinetics of liver transplant drugs in the rat model. Drug Metab Pharmacokinet 2010;25:442-9.

26. Baleriola C, Rawlinson WD, Dore GJ, Chaverot S, Stelzer-Braid S, Yoshihara M, Crawford D, Sievert W, McCaughan G, Weltman M, Cheng W, Rizkalla B, Dubois D, Thommes J, Roberts S. Effect of low-level HCV viraemia at week 24 on HCV treatment response in genotype 1 patients. Antivir Ther 2011;16:173-80.

27. Li P, Robertson TA, Thorling CA, Zhang Q, Fletcher LM, Crawford DH, Roberts MS. Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis. Drug Metab Dispos 2011;39:571-9.

28. McDonald CJ, Ostini L, Wallace DF, John AN, Watters DJ, Subramaniam VN. Iron loading and oxidative stress in the Atm-/- mouse liver. Am J Physiol Gastrointest Liver Physiol 2011;300:G554-60.

29. McDonald CJ, Wallace DF, Ostini L, Bell SJ, Demediuk B, Subramaniam VN. G80S-linked ferroportin disease: classical ferroportin disease in an Asian family and reclassification of the mutant as iron transport defective. J Hepatol 2011;54:538-44.

30. Roberts MS, Liu X, Zou Y, Siebert GA, Chang P, Whitehouse MW, Fletcher L, Crawford DH. Effect of adjuvant-induced systemic inflammation in rats on hepatic disposition kinetics of taurocholate. Am J Physiol Gastrointest Liver Physiol 2011;300:G130-6.

31. Sievert W, Dore GJ, McCaughan GW, Yoshihara M, Crawford DH, Cheng W, Weltman M, Rawlinson W, Rizkalla B, Depamphilis JK, Roberts SK. Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1. Hepatology 2011;53:1109-1117.

32. Wallace DF, McDonald CJ, Ostini L, Subramaniam VN. Blunted hepcidin response to inflammation in the absence of Hfe and transferrin receptor 2. Blood 2011;117:2960-6.

Reviews:

• Crawford D, Fletcher L, Anderson GJ. Cell specific location of Hfe:It is the 'cyte that matters. Hepatology 2008;48:336-338.

• Frazer DM, Anderson GJ, Ramm GA, Subramaniam VN, Powell LW. How much iron is too much? Expert Rev Gastroenterol Hepatol 2008;2:287-90.

• Wallace DF, Subramaniam VN. Co-factors in liver disease: the role of HFE-related hereditary hemochromatosis and iron. Biochim Biophys Acta 2009;1790:663-70.

• Wallace DF, Trinder D, Subramaniam VN. Hepcidin regulation by HFE and TFR2: is it enough to give a hepatocyte a complex? Gastroenterology 2009;137:1173-5; discussion 1175.

• Ramm GA, Ruddell RG, Subramaniam VN. Identification of ferritin receptors: their role in iron homeostasis, hepatic injury, and inflammation. Gastroenterology 2009;137:1849-51.

• Subramaniam VN. Regulation of Iron Homeostasis: Is It All in the HBD? Gastroenterology 2009;136:1449-51.

• Wallace DF, McDonald C, Subramaniam VN. Transferrin receptor 1: a ferritin receptor as well? Gastroenterology 2010;139:1052-3.

• Subramaniam VN. Hepatic HIF2 and the regulation of EPO. Gastroenterology 2011; Accepted.

Editorials:

• Farrell GC, Yeomans NN, Crawford D. Fifty years of Australian gastroenterology and hepatology: A golden era of contributions to the region. J Gastroenterol Hepatol 2009;24:1579-1586.

• Crawford D. GESA: 50 years of progress. J Gastroenterol Hepatol 2009;24:S1.

• Crawford D, Stuart K. Adding serum sodium to MELD: Identifying those most at risk. J Gastroenterol Hepatol 2009;24:1804-1806.

Invited Book Chapters:

• Crawford D, Fletcher L, Kowdley K. Iron and Liver Disease. In: Anderson GJ, McClaren G, eds. Iron Physiology and Pathophysiology in Humans. Volume In Press: Springer International, 2011.

• Wallace DF, Subramaniam VN. Non-HFE Haemochromatosis. In: Anderson GJ, McClaren G, eds. Iron Physiology and Pathophysiology in Humans: Springer International, 2011.